Dual Regulator (DIA-39-C20)
Peptide Receptor Modulator Research Series – Single, Dual, and Triple Agonist Investigational Compounds.
| Product Specifications | |
|---|---|
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight (g/mol) | 4813.45 |
| Amino Acid Count | 39 |
| Amino Acid Sequence | H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(γ-Glu-(2x AEEA)-eicosanedioyl)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Purity | ≥99% by HPLC | COA available |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in bacteriostatic water; consult COA for specific solvent recommendations |
| Storage Conditions | Store at -20°C; protect from light and moisture; reconstitute with bacteriostatic water |
For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures.
This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.
Published Literature
| # | Reference | Link |
|---|---|---|
| [01] | Coskun T., Urva S., Roell W.C., et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247.e9. |
Cell Metabolism PubMed |
| [02] | Urva S., Coskun T., Loh M.T., et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. |
Lancet PubMed |
| [03] | Rosenstock J., Frias J.P., Jastreboff A.M., et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. |
Lancet PubMed |
| [04] | Jastreboff A.M., Kaplan L.M., Frías J.P., et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N. Engl. J. Med. 2023;389(6):514–526. |
NEJM PubMed |
| [05] | Sanyal A.J., Kaplan L.M., Frias J.P., et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. |
Nature Medicine PMC Full Text PubMed |
| [06] | Coskun T., Wu Q., Schloot N.C., et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomized trial. Lancet Diabetes & Endocrinology. 2025;13(8):674–684. |
PubMed Journal |
Receptor Binding Profile
| Compound | Primary Receptor Target | Binding / Activity Profile | Reported Potency / Affinity | Functional Effect |
|---|---|---|---|---|
| Tirzepatide | GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) | Dual incretin receptor agonist; selectively binds to and activates both GIPR and GLP-1R | GIPR Ki: 0.135 nM; GLP-1R Ki: 4.23 nM. Functional assay values reported include GIPR EC50: 0.379 nM and GLP-1R EC50: 0.617 nM in Gαs recruitment assays | Activates GIPR and GLP-1R signaling, which is associated with glucose-dependent insulin secretion, reduced glucagon levels, appetite/satiety effects, and delayed gastric emptying through GLP-1R activity (Inxight Drugs) |